RxDoctor Payments Data

Taylor Stone, PA

Medical · Terre Haute, INNPI 1790175602

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,546 of the $5,190 with a category attached, or 87.6%. It is spread thinly across 24 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.

$5,190in general payments, 2019–2025

Across 182 payments — averaging $28.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$927
  • Intuitive Surgical$624
  • AstraZeneca$532
  • Novartis$508
  • E.r. Squibb & Sons, L.L.C.$424
  • Boehringer Ingelheim$340
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$62412%
  • Food & beverage$4,54688%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,190 in reported general payments places this provider in the 85th percentile of 273 medical providers in Indiana.

See all medical providers in Indiana

Medicare billing

Part B allowed, 2024
$104,715
Medicare patients
737
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$101,488
Repatha SureclickEvolocumab115$88,968
EntrestoSacubitril/Valsartan97$87,458
XareltoRivaroxaban56$48,769
JardianceEmpagliflozin41$39,598
Repatha SyringeEvolocumab17$9,438
Atorvastatin Calcium307$2,604
Ranolazine ErRanolazine34$2,567
Isosorbide Mononitrate ErIsosorbide Mononitrate275$2,498
Carvedilol370$2,101
Losartan Potassium227$1,455
Potassium Chloride27$1,318
Amlodipine Besylate217$1,301
ClopidogrelClopidogrel Bisulfate160$1,084
Spironolactone129$1,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$237$101,488130 claims
NovartisEntresto$508$87,45897 claims
Johnson & JohnsonXarelto$250$48,76956 claims
Boehringer IngelheimJardiance$340$39,59841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 273 medical providers in Indiana.

Other medical in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →